Learn to maximize profitability at contact lens meeting
December 15th 2005Leading edge programming on contact lenses, solutions, and related eye-care issues is the focal point of the fourth annual Contact Lens and Eyecare Symposium (CLES), Jan. 11 to 15, 2006, at the Royal Pacific Resort at Universal Orlando, FL.
Winners of third annual Resident Writer's Award
December 15th 2005Chicago-Jason T. Halverson, MD, of the Albert Florens Storm Eye Institute at the Medical University of South Carolina, Charleston, was named the winner of the third annual Ophthalmology Times Resident Writer's Award Program. The program was sponsored by Advanced Medical Optics (AMO). In a presentation at the Ritz Carlton Hotel in October, Dr. Halverson was the first-place winner for a case study report of traumatic mydriasis that was managed by cerclage pupilloplasty to reduce pupillary aperture.
Resident Writer's Award Winner
December 15th 2005Jason T. Halverson, MD, a senior ophthalmology resident at Albert Florens Storm Eye Institute at the Medical University of South Carolina in Charleston, was named the winner of the third annual Ophthalmology Times Resident Writer's Award Program—presented during the American Academy of Ophthalmology annual meeting in Chicago. Dr. Halverson's winning submission is featured here. He was nominated by David T. Vroman, MD, associate professor of ophthalmology, Cornea, Cataract, and Refractive Surgery, Albert Florens Storm Eye Institute, Medical University of South Carolina.
Persistent traumatic mydriasis alleviated with cerclage pupilloplasty
December 15th 2005A patient complained of severe glare and light sensitivity associated with a persistent traumatic mydriasis of the right eye. After conservative treatment with topical miotics and a painted contact lens failed to decrease the mydriasis, a cerclage pupilloplasty was performed on the right eye resulting in a 4-mm round pupil. The patient experienced significant reduction of glare and photophobia.
Intravitreal anti-VEGF drugs are step forward in AMD management
December 15th 2005The promise of 2004, that new anti-vascular endothelial growth factor (VEGF) treatments for age-related macular degeneration (AMD) be developed, came to fruition in 2005, much to the excitement of ophthalmologists. These emerging treatments for AMD took center stage this year and resulted in numerous ideas about the effect of the pharmaceutical advancements and their impact on other retinal diseases.
Glaucoma risk calculator helps with clinical decisions
December 15th 2005A newly developed glaucoma risk calculator will enhance the management of untreated ocular hypertension, said Robert N. Weinreb, MD, director, Hamilton Glaucoma Center, and distinguished professor of ophthalmology, University of California, San Diego (UCSD).
Pegaptanib benefits continue in second year of AMD trial
December 1st 2005Montr?al—The benefits observed in patients with age-related macular degeneration (AMD) after 1 year of treatment with pegaptanib sodium (Macugen, OSI/Eyetech Pharmaceuticals) continued into the second year of treatment with pegaptanib sodium and surpassed those outcomes achieved with 1 year of treatment followed by usual care and 2 years of usual care, according to Donald J. D'Amico, MD.
Favorable outcomes persist with pediatric ICL
December 1st 2005Toulouse, France—With lengthening follow-up, the posterior chamber implantable collamer lens (ICL) (STAAR Surgical) continues to be associated with encouraging results in the management of refractive amblyopia in children who have not had a response to conventional therapy with contact lenses or spectacles, said Laurence C. Lesueur, MD.
CMS ruling, new products make 2005 another banner year for cataract surgery advances
December 1st 2005Advances in techniques and technology for cataract surgery and IOL implantation have continued through the past year. Those innovations combined with changes in reimbursement have improved the practice setting, contributed to an overall air of increased optimism among ophthalmologists, and have made the contemporary era of cataract surgery more of a golden age than ever before, said I. Howard Fine, MD, reflecting on the state of cataract surgery as the year 2005 nears its end.
Are you prepared for the ABO's MOC requirements?
December 1st 2005Beginning in 2006, ophthalmologists board-certified after July 1, 1992 will transition to new Maintenance of Certification (MOC) requirements set by the American Board of Ophthalmology (ABO), which stresses lifelong learning and ongoing improvement.